New Wave of Targeted Therapies Set to Reshape High-Grade Glioma Market

Estimated at nearly USD 800 million in 2025 across the seven major markets, the high-grade glioma sector is entering a period of transformation. The United States currently leads this landscape, recording approximately 16,700 incident cases in 2025 alone. With malignant brain tumors affecting roughly 25,000 Americans annually—80% of which are gliomas—the demand for more effective, precision-based interventions has intensified.

Researchers are increasingly focusing on molecular pathways such as EGFR, IDH mutations, and BRAF alterations to develop targeted medicines. Notable candidates like FORE Biotherapeutics' Plixorafenib have already secured breakthrough designations, showing strong response rates in early trials. Similarly, Kazia Therapeutics’ Paxalisib and Northwest Therapeutics’ DCVax-L are under intense scrutiny as potential game-changers for both newly diagnosed and recurrent disease. These emerging therapies aim to address the high recurrence rates that have long hampered patient outcomes, offering a pipeline that includes cancer vaccines, CAR-T therapies, and oncolytic viruses.